Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy, Raises PT to $45
May 11, 2021 7:56 AM EDTJefferies analyst Eun Yang assumes coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Buy rating and a price target of $45.00 (from $34.00).
The analyst commented, "Building upon the management experience with AAV9-based gene therapy (Zolgensma),TSHA has an extensive pipeline for CNS... More
Taysha Gene Therapies (TSHA) Misses Q1 EPS by 31c
May 11, 2021 7:12 AM EDTTaysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.87), $0.31 worse than the analyst estimate of ($0.56).
Our team has ushered in the new year with a continued focus on achieving our corporate objectives and creating value for patients and shareholders, said RA Session II, President, Founder and CEO of Taysha. Our recent acquisition of TSHA-120 for GAN immediately transformed Taysha into a pivotal-stage gene therapy company. Based on the compelling clinical and preclinical data package generated to date for this promising product candidate, we intend to engage with regulatory agencies to discuss a pathway to... More
